Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979484 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations
A Phase 1 study of Pharmacokinetic Assessments in Healthy Volunteers, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01979484 is a Phase 1 study of Pharmacokinetic Assessments in Healthy Volunteers that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01979484, a Phase 1 study of Pharmacokinetic Assessments in Healthy Volunteers, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet.
Conditions Studied
Interventions
- DRUG PPI-668 capsule
- DRUG PPI-668 tablet
Study Locations (1)
New York
- Buffalo Clinical Research Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01979484
The ClinicalTrials.gov registry entry for NCT01979484 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presidio Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacokinetic Assessments in Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which PPI-668 capsule is the first listed.
NCT01979484 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01979484 about?
NCT01979484 is a clinical study titled "Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations". This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet.
What is the current status of trial NCT01979484?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2013-12.
What conditions does trial NCT01979484 study?
This clinical trial studies the following conditions: Pharmacokinetic Assessments in Healthy Volunteers.
What interventions are being tested in trial NCT01979484?
The interventions under investigation include: PPI-668 capsule (DRUG), PPI-668 tablet (DRUG).
Who is sponsoring clinical trial NCT01979484?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01979484 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.